Depression Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

(ABNewswire via Comtex)

DelveInsight's Depression Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Treatment-resistant depression, historical and forecasted epidemiology as well as the Treatment-resistant depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Treatment-resistant depression market report provides current treatment practices, emerging drugs, Treatment-resistant depression market share of the individual therapies, and current and forecasted depression market Si ze from 2019 to 2032 segmented by seven major markets. The Report also covers current Treatment-resistant depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Treatment-resistant depression market.

Some of the key facts of the Depression Market Report:

  •  According to Postpartum Depression, 1 in 7 women may experience postpartum depression in the year after giving birth. With approximately 4 million live births occurring each year in the United States, this equates to almost 600,000 postpartum depression diagnoses.
  • The estimated lifetime prevalence of MDD in the US is 16.2%, and the 12-month prevalence is 6.7%. Estimations about the rate of patients developing TRD vary widely from 6.6 to 35% of MDD patients. For Japan, the lifetime and 12-month prevalence rates of MDD were estimated as 3–7 and 1–2%, respectively (Mahlich et al., 2017).

 Key benefits of the Depression Market report:

  • The report covers a descriptive overview of Treatment-resistant depression, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  •  Comprehensive insight has been provided into the Treatment-resistant depression epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Treatment-resistant depression is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  •  A detailed review of the Treatment-resistant depression market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Treatment-resistant depression market

Got queries? Click here to know more about the Depression Market Landscape

Depression Market Overview

According to the National Institute of Mental Health, Depression is a common but serious mood disorder. It causes severe symptoms that affect how a person feels, thinks, and handles daily activities, such as sleeping, eating, or working. To be diagnosed with depression, the symptoms must be present for at least two weeks. According to the Centers for Disease Control and Prevention, about one out of every six adults will have depression at some time in their life. Depression affects about 16 million American adults every year. Anyone can get depressed, and depression can happen at any age and in any type of person.According to Mental Health UK, depression is a complex condition. There are different factors that can lead to it, including genetics, physical health problems, difficult childhood experiences, and stressful life events such as unemployment, the end of a relationship, or being bullied or assaulted.

There are different types of depressive disorders. The most commonly diagnosed form of depression is Major Depressive Disorder. Other major forms of depression include Persistent depressive disorder, Premenstrual dysphoric disorder, Adjustment disorder, Seasonal affective disorder (SAD), Bipolar disorder, Peripartum (Postpartum) depression, and Treatment-resistant depression, among others. Treatment of depression aims at alleviating symptoms, preventing probable suicides, improving cognition and functional status, and teaching some coping skills to the patients. Psychotherapy and pharmacotherapy, behavioral rehabilitation, and electroconvulsive therapy might be used in specific cases. 


Depression Market Epidemiological Insight

  • Depression Is a rare and potentially life-threatening disease. While it shares some signs and symptoms with other, less serious, forms of psoriasis, GPP is a separate condition and requires an accurate diagnosis, which should lead to distinct treatment and management approaches.
  • Despite the heterogeneity of rare diseases, there are common barriers to achieving accurate disease prevalence estimates. A lack of widespread awareness and accurate diagnoses, combined with research approaches that use very different data sources and non-standardized methodologies, mean that gathering insights into disease prevalence at a regional, national, or global level is challenging. Recognition of as a rare disease is increasing globally; however, describing the epidemiology of is complicated by the challenges associated with studying rare diseases.
  • As per a study by Mirza et al. (2021), The annual prevalence of GPP in a French population has been estimated at 1.76 per million. The prevalence in Japan has been estimated at 7.46 per million. 
  • According to Gordan et al. (2022), the prevalence is between 0.004% to 0.046% and this condition has a mortality range of 2% to 16%. Gordon also said that it may affect as many as 12% of those who have plaque psoriasis, and moreover, 70% of patients who have GPP also have plaque psoriasis.

Depression Market  Epidemiological Segmentation 

  •  Total Prevalent Population
  •  Stage-specific  incident
  •  Severity-specific Diagnosed Prevalence
  • Age-specific Diagnosed Prevalent Population 


Depression Market Outlook 

The Treatment-resistant depression market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Treatment-resistant depression market trends by analyzing the impact of current Treatment-resistant depression therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Treatment-resistant depression market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Treatment-resistant depression market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Treatment-resistant depression market in 7MM is expected to witness a major change in the study period 2019-2032.


Learn more by requesting for [email protected] Depression  Market Landscape

Depression Key Companies  

  •  AbbVie 
  •  Kyowa Pharma 
  •  Novartis
  •  Eilly Lilly 
  •  Mitsubishi Tanabe Pharma 
  •   Boehringer Ingelheim
  •    Janssen Pharmaceuticals 

Depression Therapies 

  •  Tremfya
  •  Lumicef
  •  Remicade
  •  Ixekizumab


 Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •   Executive Summary of Depression
  •    Disease Background and Overview
  •    Epidemiology and patient population
  •    Depression Emerging Therapies
  •    Depression  Market Outlook
  •    Market Access and Reimbursement of Therapies
  •    Appendix
  •    Depression   Report Methodology
  •       DelveInsight Capabilities
  •       Disclaimer
  •       About DelveInsight

Click here to read more ab Depression Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

comtex tracking